NDAORALTABLETPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
QULIPTA (atogepant) by AbbVie is calcitonin gene-related peptide receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QULIPTA (atogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in September 2021 for migraine prevention. It works by blocking CGRP signaling, a key pathway in migraine pathogenesis, and represents the first oral CGRP antagonist in this therapeutic class.
$0.138BPart D
Peak16.4 years to LOEProduct is at peak lifecycle stage with established commercial presence, indicating stable team structure and mature go-to-market execution rather than rapid expansion.
Mechanism of Action
Calcitonin Gene-related Peptide Receptor Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Started Sep 2026
200 enrolled
Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Started Feb 2025
420 enrolled
Chronic Migraine
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Started Feb 2025
468 enrolled
Menstrual Migraine (MM)
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Started Nov 2024
1,314 enrolled
Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Started Sep 2024
3,000 enrolled
Chronic MigraineEpisodic MigraineMigraine
Worked on QULIPTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.